UZMA ZAIDI: Open Payments
NPI 1114020096 · NORMAN, OK. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,943 in 105 payments from 16 companies in 2025. Trend: 2023 $2,192 · 2024 $1,911 · 2025 $1,943
Food & beverage: $1,943
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $606 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $279 |
| Otsuka America Pharmaceutical, Inc. | 10 | $201 |
| Alkermes, Inc. | 5 | $147 |
| Janssen Pharmaceuticals, Inc | 9 | $135 |
| Vanda Pharmaceuticals Inc. | 4 | $101 |
| Lundbeck LLC | 5 | $95 |
| Axsome Therapeutics, Inc. | 4 | $91 |
| E.R. Squibb & Sons, L.L.C. | 4 | $84 |
| Tris Pharma Inc | 3 | $68 |
Products named: VRAYLAR, REXULTI, CAPLYTA, ARISTADA, FANAPT, Auvelity, COBENFY, INVEGA SUSTENNA.
Industry payments across OK — which companies pay providers there.
